Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $41.22 Average Target Price from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus rating of “Buy” from the eight research firms that are covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is $41.22.

Several research analysts recently commented on the company. UBS Group reduced their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Denali Therapeutics in a report on Wednesday, February 28th. The Goldman Sachs Group cut their price target on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Finally, HC Wainwright decreased their price objective on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 9,589 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $17.29, for a total transaction of $165,793.81. Following the completion of the transaction, the chief executive officer now directly owns 238,067 shares of the company’s stock, valued at approximately $4,116,178.43. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Ryan J. Watts sold 9,589 shares of Denali Therapeutics stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total transaction of $165,793.81. Following the sale, the chief executive officer now directly owns 238,067 shares in the company, valued at approximately $4,116,178.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the transaction, the director now directly owns 118,043 shares in the company, valued at approximately $2,159,006.47. The disclosure for this sale can be found here. Insiders sold 110,955 shares of company stock worth $2,218,802 over the last 90 days. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC lifted its stake in Denali Therapeutics by 277.9% in the 3rd quarter. SG Americas Securities LLC now owns 35,800 shares of the company’s stock valued at $739,000 after buying an additional 26,326 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Denali Therapeutics by 11.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,679 shares of the company’s stock valued at $427,000 after purchasing an additional 2,124 shares during the last quarter. TD Asset Management Inc boosted its stake in shares of Denali Therapeutics by 59.9% during the 3rd quarter. TD Asset Management Inc now owns 135,000 shares of the company’s stock worth $2,785,000 after purchasing an additional 50,578 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Denali Therapeutics by 49.1% during the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock worth $44,000 after purchasing an additional 707 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Denali Therapeutics by 96.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock worth $73,000 after acquiring an additional 1,732 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Down 1.7 %

Shares of DNLI opened at $16.85 on Friday. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.31. The company has a 50 day moving average of $18.82 and a two-hundred day moving average of $18.84. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -15.60 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Tuesday, February 27th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same period last year, the business earned ($0.75) EPS. On average, sell-side analysts expect that Denali Therapeutics will post -2.61 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.